959 related articles for article (PubMed ID: 24064689)
1. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
2. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
[TBL] [Abstract][Full Text] [Related]
3. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
[TBL] [Abstract][Full Text] [Related]
4. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Langdahl B; Binkley N; Bone H; Gilchrist N; Resch H; Rodriguez Portales J; Denker A; Lombardi A; Le Bailly De Tilleghem C; Dasilva C; Rosenberg E; Leung A
J Bone Miner Res; 2012 Nov; 27(11):2251-8. PubMed ID: 22777865
[TBL] [Abstract][Full Text] [Related]
5. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
7. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
[TBL] [Abstract][Full Text] [Related]
8. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
9. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
[TBL] [Abstract][Full Text] [Related]
10. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
11. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
12. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
13. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
14. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
Eisman JA; Bone HG; Hosking DJ; McClung MR; Reid IR; Rizzoli R; Resch H; Verbruggen N; Hustad CM; DaSilva C; Petrovic R; Santora AC; Ince BA; Lombardi A
J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
[TBL] [Abstract][Full Text] [Related]
15. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Bone HG; Dempster DW; Eisman JA; Greenspan SL; McClung MR; Nakamura T; Papapoulos S; Shih WJ; Rybak-Feiglin A; Santora AC; Verbruggen N; Leung AT; Lombardi A
Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773
[TBL] [Abstract][Full Text] [Related]
16. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
18. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
Rizzoli R; Benhamou CL; Halse J; Miller PD; Reid IR; Rodríguez Portales JA; DaSilva C; Kroon R; Verbruggen N; Leung AT; Gurner D
Osteoporos Int; 2016 Jun; 27(6):2099-107. PubMed ID: 26879200
[TBL] [Abstract][Full Text] [Related]
19. Potential role of odanacatib in the treatment of osteoporosis.
Ng KW
Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
[TBL] [Abstract][Full Text] [Related]
20. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
Nakamura T; Shiraki M; Fukunaga M; Tomomitsu T; Santora AC; Tsai R; Fujimoto G; Nakagomi M; Tsubouchi H; Rosenberg E; Uchida S
Osteoporos Int; 2014 Jan; 25(1):367-76. PubMed ID: 23716037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]